Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

Urvi A. Shah1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkKylee Maclachlan1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkAndriy Derkach3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New YorkMeghan Salcedo1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkKelly Barnett1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkJulia Caple1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkJenna Blaslov1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkLinh Tran1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkAmanda Ciardiello1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkMiranda Burge1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkTala Shekarkhand1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkPeter Adintori4Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkJustin R. Cross5Donald B. and Catherine C. Marron Cancer Metabolism Center, Sloan Kettering Institute, New York, New YorkMatthew J. Pianko6Department of Medicine, University of Michigan, Ann Arbor, MichiganKinga Hosszu7Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New YorkDevin McAvoy7Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New YorkSham Mailankody1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkNeha Korde1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkMalin Hultcrantz1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkHani Hassoun1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkCarlyn Tan1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkSydney X. Lu8Department of Medicine, Division of Hematology, Stanford University School of Medicine, Palo Alto, CaliforniaDhwani Patel1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkBenjamin Diamond9Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FloridaGunjan L. Shah2Department of Medicine, Weill Cornell Medical College, New York, New YorkMichael Scordo2Department of Medicine, Weill Cornell Medical College, New York, New YorkOscar Lahoud2Department of Medicine, Weill Cornell Medical College, New York, New YorkDavid J. Chung2Department of Medicine, Weill Cornell Medical College, New York, New YorkHeather Landau2Department of Medicine, Weill Cornell Medical College, New York, New YorkSaad Z. Usmani1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkSergio Giralt2Department of Medicine, Weill Cornell Medical College, New York, New YorkYing Taur10Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkOla Landgren9Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FloridaGladys Block11NutritionQuest, Berkeley, CaliforniaTorin Block11NutritionQuest, Berkeley, CaliforniaJonathan U. Peled2Department of Medicine, Weill Cornell Medical College, New York, New YorkMarcel R.M. van den Brink2Department of Medicine, Weill Cornell Medical College, New York, New YorkAlexander M. Lesokhin1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
2022en
ABI

Annotatsiya

PURPOSE: Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We hypothesized that dietary factors affect the microbiome (abundance of butyrate-producing bacteria or stool butyrate concentration) and may be associated with multiple myeloma outcomes. EXPERIMENTAL DESIGN: We examined the relationship of dietary factors (via a food frequency questionnaire), stool metabolites (via gas chromatography-mass spectrometry), and the stool microbiome (via 16S sequencing - α-diversity and relative abundance of butyrate-producing bacteria) with sustained MRD negativity (via flow cytometry at two timepoints 1 year apart) in myeloma patients on lenalidomide maintenance. The Healthy Eating Index 2015 score and flavonoid nutrient values were calculated from the food frequency questionnaire. The Wilcoxon rank sum test was used to evaluate associations with two-sided P < 0.05 considered significant. RESULTS: At 3 months, higher stool butyrate concentration (P = 0.037), butyrate producers (P = 0.025), and α-diversity (P = 0.0035) were associated with sustained MRD negativity. Healthier dietary proteins, (from seafood and plants), correlated with butyrate at 3 months (P = 0.009) and sustained MRD negativity (P = 0.05). Consumption of dietary flavonoids, plant nutrients with antioxidant effects, correlated with stool butyrate concentration (anthocyanidins P = 0.01, flavones P = 0.01, and flavanols P = 0.02). CONCLUSIONS: This is the first study to demonstrate an association between a plant-based dietary pattern, stool butyrate production, and sustained MRD negativity in multiple myeloma, providing rationale to evaluate a prospective dietary intervention.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba